Loading organizations...
Protein Forest develops and markets specialized instruments, consumables, and software platforms for advanced protein separation and bioanalysis. The company focuses on digital fractionation systems, enabling scientists to precisely manage and analyze complex protein samples. Their offerings provide enhanced resolution and throughput for research applications, positioning them as a key provider of tools designed to streamline intricate biological workflows in laboratory settings.
The company was co-founded in 2002 by Gleb Zilberstein and John L. Zabriskie. Their foundational insight stemmed from the critical need for more sophisticated and efficient methods to handle and separate proteins, a bottleneck in various life science research fields. Zilberstein and Zabriskie leveraged their expertise to create a company dedicated to pushing the boundaries of protein analysis technology, aiming to simplify complex preparatory stages for downstream assays.
Protein Forest primarily serves scientific researchers across academic institutions and pharmaceutical companies, providing them with essential tools for discovery and development. The company's long-term vision centers on empowering scientists with precise, reliable, and user-friendly solutions that accelerate advancements in proteomics and related biotechnologies. They aim to continue innovating within the protein analysis space, supporting ongoing efforts to understand disease mechanisms and develop new therapeutics.
Protein Forest has raised $19.0M across 1 funding round.
Protein Forest has raised $19.0M in total across 1 funding round.
Protein Forest has raised $19.0M in total across 1 funding round.
Protein Forest's investors include Flare Capital Partners.
Protein Forest has raised $19.0M across 1 funding round. Most recently, it raised $19.0M Series A in November 2003.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2003 | $19M Series A | — | Flare Capital Partners | Announced |
Protein Forest is a biotechnology company specializing in sample fractionation technologies for proteomics, offering instruments, consumables, and software to enhance protein analysis.[1][2][3] Its flagship digital ProteomeChip (dPC™) platform uses parallel isoelectric focusing to rapidly fractionate proteins by their isoelectric points, improving sensitivity in techniques like mass spectrometry, chromatography, and immunoblotting.[1][2][4] The company serves scientists in the US and internationally, addressing challenges in separating complex protein mixtures for bioanalysis and drug discovery.[2][3]
Protein Forest solves key bottlenecks in protein extraction and purification by providing faster, easier-to-use tools based on electrophoresis principles, enabling reproducible resolution of proteins from cells or tissues.[1][6] It targets proteomics researchers, biopharma, and life sciences labs, with growth evidenced by patent filings, regional expansions like into North East England, and a focus on quantitative applications such as Western blotting.[4][5]
Protein Forest emerged from scientific innovations in proteomics, developing its core digital ProteomeChip™ technology—a microchip for accurate protein resolution via parallel isoelectric focusing.[1][4][6] Scientists at the company pioneered this breakthrough to overcome limitations in traditional electrophoresis, making fractionation quicker and more reliable for downstream analyses.[1][3]
Key milestones include patent filings for chip-based quantitative Western blotting and expansions into new markets, such as North East England, to bolster regional biotech capabilities with its fractionator equipment and software.[4][5] While specific founding year and founders are not detailed in available sources, the company's evolution centers on integrating hardware with bioinformatics software for life sciences applications.[3]
Protein Forest rides the proteomics boom, fueled by advances in mass spectrometry and personalized medicine demanding high-throughput protein analysis for drug discovery and biomarker identification.[1][2][3] Timing aligns with biopharma's shift toward targeted therapies like PROTACs and antibody-drug conjugates, where efficient protein separation is critical—market forces like rising R&D in structural biology amplify this.[2]
The company influences the ecosystem by equipping labs with vendor-agnostic tools that streamline workflows, competing with reagent marketplaces and discovery services while enabling faster hit-to-candidate pipelines.[2] Its expansions strengthen regional biotech hubs, contributing to global life sciences infrastructure.[5]
Protein Forest is poised for expansion through dPC™ commercialization, leveraging patents and software integrations to capture proteomics market share amid AI-driven bioanalysis trends.[1][3][4] Upcoming trends like multi-omics integration and automated labs will shape its path, potentially via partnerships with biopharma for drug screening.
Its influence may grow by dominating fractionation niches, evolving from tools provider to proteomics platform leader—building on its technological breakthrough to power next-gen discoveries.[1][6]
